Treatment with activated protein C (aPC) is protective during the development of myocardial fibrosis: an angiotensin II infusion model in mice.
Myocardial fibrosis contributes to the development of heart failure. Activated Protein C (aPC) is a circulating anticoagulant with anti-inflammatory and cytoprotective properties. Using a model of myocardial fibrosis second to Angiotensin II (AngII) infusion, we investigated the novel therapeutic fu...
Main Authors: | Mryanda J Sopel, Nicole L Rosin, Alec G Falkenham, Michael Bezuhly, Charles T Esmon, Timothy D G Lee, Robert S Liwski, Jean-Francois Légaré |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3446915?pdf=render |
Similar Items
-
Highly purified human peripheral blood monocytes produce IL-6 but not TNFα in response to angiotensin II
by: Laura Gelinas, et al.
Published: (2011-09-01) -
Connective tissue growth factor expression after angiotensin II exposure is dependent on transforming growth factor-β signaling via the canonical Smad-dependent pathway in hypertensive induced myocardial fibrosis
by: Chloe Kok Sum Wong, et al.
Published: (2018-03-01) -
Factor VII, EPCR, aPC Modulators: novel treatment for neuroinflammation
by: Valery Golderman, et al.
Published: (2022-06-01) -
Recruitment of macrophages from the spleen contributes to myocardial fibrosis and hypertension induced by angiotensin II
by: Ning-Ping Wang, et al.
Published: (2017-05-01) -
Angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice
by: Naoya Kakutani, et al.
Published: (2020-04-01)